Long-Term Impact of COVID-19 ARDS: Four-Year Outcomes and Quality of Life

Four years after intensive care unit (ICU) admission for COVID-19-associated acute respiratory distress syndrome (ARDS), a significant proportion of patients continue to experience high mortality rates and diminished quality of life, according to a recent study published in Scientific Reports. The research highlights the lasting health consequences faced by individuals who required advanced respiratory support during the peak of the pandemic.

Background and the Scope of the Problem

During the height of the COVID-19 pandemic, approximately 15% of patients developed respiratory failure severe enough to require invasive or non-invasive ventilation, or high-flow nasal oxygen therapy. While acute ICU mortality has been a concern, the long-term effects on survivors remained largely unknown, particularly in regions like Central and Eastern Europe where healthcare resources and rehabilitation services may differ from those in Western countries. Previous studies have indicated persistent fatigue, shortness of breath and cognitive difficulties among COVID-19 survivors, but the trajectory of these impairments over time was unclear.

Study Design and Methodology

Researchers conducted a retrospective–prospective cohort study at a temporary hospital in Zielona Góra, Poland, evaluating 283 adults admitted with COVID-19-associated ARDS between December 2020 and July 2021. Data collected included demographics, pre-existing conditions, vital signs, respiratory parameters, and laboratory markers. The study followed patients for four years, assessing mortality at 30 days and four years post-ICU admission. Follow-up interviews were completed for 81 of 157 confirmed four-year survivors, gathering information on functional status, quality of life, fatigue, cognitive function, return to work, rehabilitation use, and financial burden.

Several tools were used to assess patient outcomes, including the post-COVID-19 functional status (PCFS) scale, the modified Medical Research Council (mMRC) scale for dyspnea, and the EuroQol-5 Dimension instrument (EQ-5D-5L) and EuroQol visual analogue scale (EQ-VAS) for quality of life.

Key Findings: Mortality Rates

The study revealed a 30-day mortality rate of 29.0%. Cumulative four-year mortality reached 44.5%, accounting for both early deaths in the ICU and subsequent deaths during the follow-up period. Older age and higher white blood cell (WBC) count at ICU admission were identified as significant predictors of both 30-day and late mortality. Specifically, older age remained independently associated with late mortality.

Long-Term Health and Quality of Life

Among the four-year survivors, a substantial proportion reported ongoing health challenges. Approximately 30% experienced functional limitations, and 47% reported insomnia. Clinically relevant fatigue was reported by 27.5%, while 21.3% reported moderate or worse discomfort/pain. Notably, 15% had not returned to full-time work. Around 39% of survivors had received rehabilitation, and 30% were re-hospitalized at least once. The median quality-adjusted life years (QALYs) were estimated at 3.7 years.

Patients with cognitive complaints, those who underwent rehabilitation, or those experiencing fatigue or dyspnea, and those who did not return to full-time work, tended to have lower QALYs, potentially reflecting greater baseline impairment.

Implications and Future Directions

The findings underscore the substantial and lasting impact of COVID-19 ARDS on patient outcomes. The high four-year mortality rate and the prevalence of long-term symptoms highlight the need for continued monitoring and support for survivors. Further research is needed to identify effective interventions to improve quality of life and functional status in this vulnerable population. The study emphasizes the importance of addressing the long-term consequences of the pandemic and ensuring adequate access to rehabilitation services and ongoing care.

Journal Reference: Zawadzki, J., Kania, J., Murkos, M., Zgoła, D., Noga, A., Nowak, P., Kulińska, W., Pawlik, P., & Kudliński, B. (2026). Four year mortality and quality of life after ICU treatment for COVID 19 related acute respiratory distress syndrome. Scientific Reports. DOI: 10.1038/s41598-026-42341-1